Elevation Oncology to Present at 2024 Citizens JMP Life Sciences Conference

BOSTON, May 7, 2024 -- Elevation Oncology, Inc. (Nasdaq: ELEV), a pioneering company in the oncology sector, is committed to the discovery and development of specialized cancer treatments aimed at addressing the needs of patients with various solid tumors who currently have limited treatment options. The company has announced that its Chief Executive Officer, Joseph J. Ferra, will take part in a fireside chat at the Citizens JMP Life Sciences Conference. This event is scheduled for Tuesday, May 14, 2024, at 11:30 am ET.

The chat will be accessible through a live webcast, with a replay available on the Events page of Elevation Oncology's Investor Relations website.

About Elevation Oncology, Inc.
Elevation Oncology is dedicated to creating innovative cancer therapies, especially for patients with significant unmet medical needs across a variety of solid tumors. The company's expertise lies in the development of antibody-drug conjugates (ADCs), which are designed to deliver targeted cancer treatment. Elevation Oncology is actively working on a unique pipeline aimed at two clinically validated targets in oncology: Claudin 18.2 and HER3.

The company's leading candidate, EO-3021, is an ADC specifically designed to target Claudin 18.2. This drug is currently undergoing evaluation in a Phase 1 clinical trial (NCT05980416). The trial focuses on patients with advanced, unresectable, or metastatic solid tumors that are likely to express Claudin 18.2. This includes patients with gastric, gastroesophageal junction, pancreatic, or esophageal cancers. Encouragingly, Elevation Oncology plans to nominate a development candidate for its second program, which targets HER3, another crucial marker in oncology. This new HER3-targeting ADC is intended to treat patients with solid tumors that overexpress HER3 and is expected to enter further development in 2024.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!